Literature DB >> 22001604

Viral vectors for gene delivery to the central nervous system.

Thomas B Lentz1, Steven J Gray, R Jude Samulski.   

Abstract

The potential benefits of gene therapy for neurological diseases such as Parkinson's, Amyotrophic Lateral Sclerosis (ALS), Epilepsy, and Alzheimer's are enormous. Even a delay in the onset of severe symptoms would be invaluable to patients suffering from these and other diseases. Significant effort has been placed in developing vectors capable of delivering therapeutic genes to the CNS in order to treat neurological disorders. At the forefront of potential vectors, viral systems have evolved to efficiently deliver their genetic material to a cell. The biology of different viruses offers unique solutions to the challenges of gene therapy, such as cell targeting, transgene expression and vector production. It is important to consider the natural biology of a vector when deciding whether it will be the most effective for a specific therapeutic function. In this review, we outline desired features of the ideal vector for gene delivery to the CNS and discuss how well available viral vectors compare to this model. Adeno-associated virus, retrovirus, adenovirus and herpesvirus vectors are covered. Focus is placed on features of the natural biology that have made these viruses effective tools for gene delivery with emphasis on their application in the CNS. Our goal is to provide insight into features of the optimal vector and which viral vectors can provide these features.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22001604      PMCID: PMC3293995          DOI: 10.1016/j.nbd.2011.09.014

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  190 in total

Review 1.  Retrovirus receptors.

Authors:  Maja A Sommerfelt
Journal:  J Gen Virol       Date:  1999-12       Impact factor: 3.891

2.  Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization.

Authors:  L Sun; J Li; X Xiao
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

3.  A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation.

Authors:  D Duan; Y Yue; Z Yan; J F Engelhardt
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

4.  Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy.

Authors:  Z Yan; Y Zhang; D Duan; J F Engelhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-06       Impact factor: 11.205

5.  Pseudotyping of glycoprotein D-deficient herpes simplex virus type 1 with vesicular stomatitis virus glycoprotein G enables mutant virus attachment and entry.

Authors:  D B Anderson; S Laquerre; K Ghosh; H P Ghosh; W F Goins; J B Cohen; J C Glorioso
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

6.  Retrograde axonal transport of herpes simplex virus: evidence for a single mechanism and a role for tegument.

Authors:  E L Bearer; X O Breakefield; D Schuback; T S Reese; J H LaVail
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

7.  Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors.

Authors:  H Nakai; T A Storm; M A Kay
Journal:  Nat Biotechnol       Date:  2000-05       Impact factor: 54.908

8.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Authors:  J M Markert; M D Medlock; S D Rabkin; G Y Gillespie; T Todo; W D Hunter; C A Palmer; F Feigenbaum; C Tornatore; F Tufaro; R L Martuza
Journal:  Gene Ther       Date:  2000-05       Impact factor: 5.250

Review 9.  Mechanisms for Env glycoprotein acquisition by retroviruses.

Authors:  Marc C Johnson
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-22       Impact factor: 2.205

10.  Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system.

Authors:  B L Davidson; C S Stein; J A Heth; I Martins; R M Kotin; T A Derksen; J Zabner; A Ghodsi; J A Chiorini
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  82 in total

Review 1.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

2.  Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex.

Authors:  Annelies Gerits; Pascaline Vancraeyenest; Samme Vreysen; Marie-Eve Laramée; Annelies Michiels; Rik Gijsbers; Chris Van den Haute; Lieve Moons; Zeger Debyser; Veerle Baekelandt; Lutgarde Arckens; Wim Vanduffel
Journal:  Neurophotonics       Date:  2015-10-01       Impact factor: 3.593

Review 3.  Direct lineage conversion of astrocytes to induced neural stem cells or neurons.

Authors:  Yanhua Huang; Sheng Tan
Journal:  Neurosci Bull       Date:  2015-04-08       Impact factor: 5.203

Review 4.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

5.  Targeted delivery of self-complementary adeno-associated virus serotype 9 to the brain, using magnetic resonance imaging-guided focused ultrasound.

Authors:  Emmanuel Thévenot; Jessica F Jordão; Meaghan A O'Reilly; Kelly Markham; Ying-Qi Weng; Kevin D Foust; Brian K Kaspar; Kullervo Hynynen; Isabelle Aubert
Journal:  Hum Gene Ther       Date:  2012-10-15       Impact factor: 5.695

6.  A gammaherpesvirus establishes persistent infection in neuroblastoma cells.

Authors:  Hye-Jeong Cho; Moon Jung Song
Journal:  Mol Cells       Date:  2014-06-30       Impact factor: 5.034

Review 7.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

8.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

Review 9.  Recent gene therapy advancements for neurological diseases.

Authors:  Sahana Nagabhushan Kalburgi; Nadia N Khan; Steven J Gray
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

Review 10.  Nonhuman Primate Optogenetics: Recent Advances and Future Directions.

Authors:  Adriana Galvan; William R Stauffer; Leah Acker; Yasmine El-Shamayleh; Ken-Ichi Inoue; Shay Ohayon; Michael C Schmid
Journal:  J Neurosci       Date:  2017-11-08       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.